Evidence map›Paper›PMID 37061119›Full record

ArticleCancer letters2023

m

Angelica Benavides-Serrato, Jacquelyn T Saunders, Sunil Kumar, Brent Holmes, Kennedy E Benavides, Muhammad T Bashir, Robert N Nishimura, Joseph Gera

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Small molecule inhibitors targeting mJournal of hematology & oncology · 2024
    Review
  11. Review
  12. SINEUPs to boost translation.Molecular therapy. Nucleic acids · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Angelica Benavides-SerratoDepartment of Medicine, University of California, Los Angeles, CA, USA; Department of Research & Development, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA.
Jacquelyn T SaundersDepartment of Research & Development, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA.
Sunil KumarDepartment of Research & Development, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA.
Brent HolmesDepartment of Research & Development, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA.
Kennedy E BenavidesDepartment of Research & Development, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA.
Muhammad T BashirDepartment of Medicine, University of California, Los Angeles, CA, USA; Department of Research & Development, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA.
Robert N NishimuraNeurology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA, USA; Department of Research & Development, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA.
Joseph GeraDepartment of Medicine, University of California, Los Angeles, CA, USA; Jonnson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA; Molecular Biology Institute, University of California, Los Angeles, CA, USA; Department of Research & Development, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA. Electronic address: jgera@mednet.ucla.edu.
University of California, Los Angeles · USVA Greater Los Angeles Healthcare System · US

Funding

Co-targeting mTOR and YAP signaling in glioblastomaR01CA217820 · NCI · GREATER LOS ANGELES VETERANS RESEARCH AND EDUCATION FOUNDATION · PI GERA, JOSEPH F · 2018 to 2022
$1.6M
Mechanisms of Resistance to mTOR-Targeted TherapiesI01BX002665 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI GERA, JOSEPH F · 2014 to 2025
–
BLRD VA I01 BX002665NCI NIH HHS R01 CA217820
6 · The paper itself

Abstract

A major mechanism conferring resistance to mTOR inhibitors is activation of a salvage pathway stimulating internal ribosome entry site (IRES)-mediated mRNA translation, driving the synthesis of proteins promoting resistance of glioblastoma (GBM). Previously, we found this pathway is stimulated by the requisite IRES-trans-acting factor (ITAF) hnRNP A1, which itself is subject to phosphorylation and methylation events regulating cyclin D1 and c-myc IRES activity. Here we describe the requirement for m

Indexed as

Cyclin D1GlioblastomaGenes, mycHeterogeneous Nuclear Ribonucleoprotein A1HumansInternal Ribosome Entry SitesMethyltransferasesProtein BiosynthesisTOR Serine-Threonine KinasesCyclin D1Heterogeneous Nuclear Ribonucleoprotein A1Internal Ribosome Entry SitesMethyltransferasesMETTL3 protein, humanMTOR protein, humanTOR Serine-Threonine KinasesDrug resistanceGlioblastomaIRESITAFmTOR inhibitorsN(6)-methyladenosine modification

Identifiers

PMID37061119
PMCPMC10805108
OpenAlexW4365517285

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.